HomeBusinessConsumer Services Industry & Stock NewsCytokinetics (CYTK) CEO On Future Of Heart Disease Treatment

Cytokinetics (CYTK) CEO On Future Of Heart Disease Treatment

Cytokinetics (CYTK) CEO Robert Blum joins Nicole Petallides to give an overview of the company and discusses its Aficamten trial. He talks about how the Sequoia-HCM Phase 3 clinical trial showed the best-case scenario result for obstructive hypertrophic cardiomyopathy. He goes over the future of heart disease treatment. Cytokinetics is a biopharma company with a focus on muscle activators and inhibitors as potential disease treatments. Tune in to find out more about the stock market today.

Trading 360

03 Jan 2024

SHARE

ON AIR
3:30 am
Trading 360
replay
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
ON AIR
3:30 am
Trading 360
REPLAY
4:30 am
Next Gen Investing
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
Fast Market
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
7:00 pm
Market Overtime
REPLAY
education
7:30 pm
Your First Trade
REPLAY
8:00 pm
Trading 360
REPLAY
9:00 pm
Market Overtime
REPLAY
education
9:30 pm
Your First Trade
REPLAY
10:00 pm
Fast Market
REPLAY
11:00 pm
Trading 360
REPLAY

Get the Market Minute

Daily insights for every investor

coming soon

We are now

coming soon

We are now